Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
March 17, 2024 21:00 ET
|
Fennec Pharmaceuticals Inc.
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
March 13, 2024 11:42 ET
|
Eloxx Pharmaceuticals
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready...
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
March 12, 2024 08:30 ET
|
Allogene Therapeutics, Inc.
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025...
PMB Aerospace Corporation Announces Exclusive License of Battery Technology
March 11, 2024 08:00 ET
|
PMB Aerospace Corporation
PMB AEROSPACE CORPORATION ANNOUNCES EXCLUSIVE LICENSE OF BATTERY TECHNOLOGY
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
March 11, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
Nurix's Phase 1a/1b study of NX-2127 in adults with r/r B-cell malignancies to enroll new patients after partial clinical hold lifted
Aussie Vapes Granted Import License in Australia
March 08, 2024 07:00 ET
|
Lifeist Wellness Inc.
TORONTO, March 08, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in...
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
March 07, 2024 07:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
CPS Technologies and Triton Systems Announce New Licensing Agreement
March 06, 2024 08:00 ET
|
CPS Technologies Corp.
NORTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) (“CPS”) and Triton Systems, Inc. (“Triton”) today announced they have signed a manufacturing licensing...
Kraig Biocraft Laboratories Preparing Additional Business Investment License to Advance its Business Operations
March 06, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Labs (OTCQB:KBLB) expects to submit its second business investment application in Vietnam as part of the planned expansion of its business operations
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 04, 2024 07:00 ET
|
C4 Therapeutics, Inc.
Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery...